NCT02306798View on ClinicalTrials.gov

TP0502-B-Pharmaco-Scintigraphic-Study

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

December 31, 2013

Conditions
Ulcerative Colitis
Interventions
DRUG

TP05

One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast

All Listed Sponsors
lead

Tillotts Pharma AG

INDUSTRY

NCT02306798 - TP0502-B-Pharmaco-Scintigraphic-Study | Biotech Hunter | Biotech Hunter